{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:39:36Z","timestamp":1784702376284,"version":"3.55.0"},"reference-count":71,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Antipsychotic-induced weight gain (AIWG) is a major concern in psychiatry, where there is a mortality gap between those with mental illness, particularly schizophrenia, and the general population. One development proposed is using centrally-acting opioid receptor antagonists (CORAs) such as naltrexone and samidorphan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The systematic review and meta-analysis evaluated the available human clinical trial data on the effect of CORA on AIWG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>Four online databases (MEDLINE, EMBASE, PsycINFO, and Cochrane) were searched for randomized-controlled trials (RCTs) on the topic. The primary outcome was change in bodyweight. Secondary anthropometric outcomes included percentage bodyweight change, BMI change, and absolute risk of weight gain. Meta-analysis was conducted on primary outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Nine RCT articles (samidorphan\u2009=\u20096, naltrexone\u2009=\u20093) and two extension studies from RCTs (both samidorphan) were identified. Meta-analysis of four RCTs (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091416) found olanzapine\/samidorphan was associated with less weight gain than olanzapine alone (mean difference in bodyweight change: \u22121.18\u2009kg; 95% CI: \u22121.67 to \u22120.68). Olanzapine\/samidorphan was also superior to olanzapine for changes in BMI (\u22120.65\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; 95% CI: \u22121.1 to \u22120.28), waist circumference (\u22121.5\u2009cm; 95% CI: \u22122.67 to \u22120.32), and risk reduction for gaining 7% body weight (\u221212.4%; 95% CI: \u221218.27 to \u22126.54) or 10% body weight (\u221210.8%; 95% CI: \u221216.21 to \u22125.45). Naltrexone did not separate from placebo for change in weight or BMI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>CORA, specifically samidorphan, was effective at reducing weight gain in individuals prescribed olanzapine. The small effect sizes and discrepancy between samidorphan and naltrexone suggest effects may be timing dependent, not a class effect, or dependent on the antipsychotic combination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251337374","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T06:21:27Z","timestamp":1747981287000},"page":"790-803","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Centrally-acting opioid receptor antagonists as a treatment for antipsychotic-induced weight gain: A systematic review and meta-analysis of clinical trial data"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-5494","authenticated-orcid":false,"given":"Kenn","family":"Lee","sequence":"first","affiliation":[{"name":"Pennine Care NHS Foundation Trust, Mental Health Liaison Team, Fairfield General Hospital, Bury, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Twohig","sequence":"additional","affiliation":[{"name":"Greater Manchester Mental Health NHS Foundation Trust, Rehabilitation Services, Royal Bolton Hospital, Bolton, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguemo Pauline","family":"Idoko","sequence":"additional","affiliation":[{"name":"Lancashire and South Cumbria NHS Foundation Trust, Perinatal Psychiatry, Chorley and South Ribble District General Hospital, Chorley, Lancashire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3144-5390","authenticated-orcid":false,"given":"Benjamin David","family":"Williams","sequence":"additional","affiliation":[{"name":"Greater Manchester Mental Health NHS Foundation Trust, Psychiatric Intensive Care Unit, North Manchester General Hospital, Crumpsall, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769309"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.042853"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2020) The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia 3rd edn. Washington DC: American Psychiatric Association Publishing. Available at: https:\/\/psychiatryonline.org\/doi\/book\/10.1176\/appi.books.9780890424841 (accessed 11 August 2024).","DOI":"10.1176\/appi.books.9780890424841"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.97"},{"key":"e_1_3_3_6_1","unstructured":"Centers for Disease Control and Prevention (2022) Consequences of obesity. Available at: https:\/\/www.cdc.gov\/obesity\/basics\/consequences.html (accessed 9 August 2024)."},{"key":"e_1_3_3_7_1","article-title":"Body mass index and mortality in patients with schizophrenia spectrum disorders: A cohort study in a South London catchment area","volume":"35","author":"Chen J","year":"2022","unstructured":"Chen J, Perera G, Shetty H, et al. (2022) Body mass index and mortality in patients with schizophrenia spectrum disorders: A cohort study in a South London catchment area. Gen Psychiatr 35: e100819.","journal-title":"Gen Psychiatr"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111569"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.2307\/1267913"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2010.10.010"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.19121279"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20994"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbac144"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119856850"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S113099"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1049-5"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4326-12.2013"},{"key":"e_1_3_3_19_1","unstructured":"European Medicines Agency (2024) Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8\u201311 April 2024 | European Medicines Agency (EMA). Available at: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024 (accessed 11 August 2024)."},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2004.00131.x"},{"key":"e_1_3_3_21_1","volume-title":"METAN: Stata Module for Fixed and Random Effects Meta-Analysis. Statistical Software Components","author":"Fisher D","year":"2024","unstructured":"Fisher D, Harris R, Bradburn M, et al. (2024) METAN: Stata Module for Fixed and Random Effects Meta-Analysis. Statistical Software Components. Boston, MA: Boston College Department of Economics."},{"key":"e_1_3_3_22_1","article-title":"Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity","author":"Food and Drug Association","year":"2024","unstructured":"Food and Drug Association (2024) Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. Food Drug Association. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type (accessed 10 August 2024).","journal-title":"Food Drug Association"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-8343(00)00081-5"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.02.003"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13945"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_3_3_27_1","unstructured":"JASP Team (2024) JASP (Version 0.18.3) [Computer Software]. Available at: https:\/\/jasp-stats.org"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2021.04.009"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14674"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1153648"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.11.003"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1359786810382058"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2539"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2022.07.006"},{"key":"e_1_3_3_35_1","unstructured":"Lee K Idoko N Twohig M et al. (2023) Systematic review of the efficacy of opioid receptor antagonists at treating antipsychotic-induced weight gain. Available at: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=455663 (accessed 10 August 2024)."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjb.2023.29"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00181"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.18030280"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.573479"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2295397"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852922000967"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.91"},{"key":"e_1_3_3_43_1","unstructured":"NHS England (2024) Improving the physical health of people living with severe mental illness. Available at: https:\/\/www.england.nhs.uk\/long-read\/improving-the-physical-health-of-people-living-with-severe-mental-illness\/ (accessed 9 August 2024)."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-00463-7"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338163"},{"key":"e_1_3_3_46_1","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. (2021) PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ 372: n160.","journal-title":"BMJ"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10122366"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201100092"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32316-5"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.0334"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12769"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.10.010"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11970"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.19091000"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-018-2485-z"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.10.1123"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.10.014"},{"key":"e_1_3_3_59_1","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. (2016) ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355: i4919.","journal-title":"BMJ"},{"key":"e_1_3_3_60_1","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366: l4898.","journal-title":"BMJ"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S373195"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113509904"},{"key":"e_1_3_3_63_1","first-page":"125","volume-title":"The Maudsley Practice Guidelines for Physical Health Conditions in Psychiatry","author":"Taylor D","year":"2020","unstructured":"Taylor D, Gaughran F, Pillinger T (eds) (2020) Treatment of antipsychotic-induced weight gain. In: The Maudsley Practice Guidelines for Physical Health Conditions in Psychiatry. Hoboken, NJ: John Wiley & Sons, Inc, pp. 125\u2013130."},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000192"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4764-9"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01694-7"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-022516-034110"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02672-2"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294974"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852920001376"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-7634(02)00041-6"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-1286-1_2"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251337374","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251337374","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251337374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:11Z","timestamp":1777507931000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251337374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/02698811251337374"],"URL":"https:\/\/doi.org\/10.1177\/02698811251337374","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}